Navigation Links
TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:12/10/2007

Final Data from Pivotal Study Presented at 49th American Society of

Hematology Meeting

FRAZER, Pa., Dec. 10 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) announced today that in a pivotal study of patients with indolent non-Hodgkin's lymphoma (NHL), whose disease has progressed during or following treatment with rituximab, TREANDA (bendamustine HCl) induced a high rate of response. TREANDA(R) is a novel investigational chemotherapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed in 2007 with indolent NHL, a serious and slow growing cancer of the lymphatic system that is difficult to treat because patients are prone to relapse after treatment. The final data from this multicenter study were presented at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, GA [Poster # 505-I; Abstract #1351].

"The high response rate in this study suggest that bendamustine could offer substantial periods of remission to patients with indolent NHL whose cancer is progressing after treatment with rituximab," said Brad Kahl, MD, Associate Professor, Director Lymphoma Service, University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, and the lead investigator of this study. "Because many patients with NHL eventually become resistant to treatment with rituximab and other therapies, new treatments are always required."

In this pivotal study of 100 patients with indolent NHL whose disease has progressed during or following treatment with rituximab, or a rituximab- containing regimen, as assessed by an independent radiological committee, 75 patients had a response. Of those patients who responded to treatment, 14 had a complete response and three had an unconfirmed complete response. The median duration of response was 9.2 months. Bendamustine demonstrated a manageable tolerability profile. As would be expected of a chemothera
'/>"/>

SOURCE Cephalon Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
2. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
3. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
4. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
11. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)...  Specialty Coating Systems is pleased to ... technologies: SCS microRESIST™ Antimicrobial Parylene Technology. SCS ... antimicrobial properties to effectively eliminate harmful microorganisms ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... to pose a challenge to hospitals and ...
(Date:6/18/2013)... 18, 2013  In a letter to authorities at her ... Lake View, Iowa , writes that a ... vaccine is neither scientifically justified nor ethically sound. ... summer issue of the Journal of American Physicians ... correct, and an average of 36,000 patients per year die ...
(Date:6/18/2013)... BURLINGTON, Mass. , June 18, 2013 /PRNewswire/ ... and advisory firms for pharmaceutical and healthcare issues, ... includes coverage of the Middle East ... Market Access Tracker analyzes the challenges and opportunities ... in four international regions comprising 24 countries. The ...
Breaking Medicine Technology:Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2Mandated Flu Vaccine for Hospital Workers Ethically Questionable, Surgeon Writes 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 2Decision Resources' Market Access Tracker Now Covers the Middle East and Africa 3
... Conn., Feb. 14, 2012  UBM Medica,s MusculoskeletalNetwork ... updates on management of musculoskeletal disorders, now features a ... 2012 Annual Meeting of the American Academy of Orthopaedic ... California. The AAOS conference offers orthopedists a ...
... professional athletes are not the only people who are ... Physicians are often paid for their signature too – ... employment contract. (Logo:  http://photos.prnewswire.com/prnh/20120214/DA52850LOGO ) ... an average of more than $20,000 to sign on ...
Cached Medicine Technology:UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 2UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 3How Much is Your Signature Worth? Physicians Command $21,000 on Average To Sign for Employment 2
(Date:6/18/2013)... NY (PRWEB) June 18, 2013 Cheap Concert ... for the tournament which gets underway in July. ... on any CONCACAF ticket order. , The popularity ... cranny of the globe.    In fact, the hype of the game ... Its popularity also trickled down the veins of fans from ...
(Date:6/18/2013)... 2013 As obesity rates sky rocket in ... surgical equipment during childbirth comes as no shock. Forceps are ... mother when she is unable to do so herself and ... with higher rates of complication for both the mother and ... the mother and child, forceps births add to the pressure ...
(Date:6/18/2013)... Albany, New York (PRWEB) June 19, 2013 ... provides comprehensive understanding and unprecedented access to the drug ... worlds leading healthcare companies. , The report provides ... companies enter drug delivery partnering deals. The majority of ... obtains a right or an option right to license ...
(Date:6/18/2013)... 2013 Parker Waichman LLP , ... of victims injured by defective medical devices, reports that ... Infuse bone graft products are now available. Published this ... the two studies serve up two key findings: There ... Infuse and the traditional bone graft; and there is ...
(Date:6/18/2013)... Tarrytown, NY (PRWEB) June 18, 2013 ... simply to grow in size. Quite the opposite. ... and audiology practice-with over 140 expertly trained physicians offering ... communities in 40 locations throughout the Greater New York ... the important circumstances are right. And that includes the ...
Breaking Medicine News(10 mins):Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 2Health News:CONCACAF Tickets Have Been Released for Martinique, Mexico, Panama, El Salvador, Trinidad, Tobago, Haiti, Honduras, Costa Rica, Cuba, Belize, US, Canada, Honduras & Cuba 3Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5
... HealthDay Reporter , TUESDAY, Oct. 18 (HealthDay News) -- ... areas of the brain that are larger than those ... researchers say. "We were interested in understanding whether ... in brain structure and function," lead researcher Dr. Geraint ...
... , WEDNESDAY, Oct. 19 (HealthDay News) -- Although ... risk that their baby will be born with birth defects, ... the condition will not raise that risk any further. ... blood pressure medications known as angiotensin-converting enzyme (ACE) inhibitors are ...
... the leading cause of death in the United States, and ... addition, fewer than half of the small percentage of people ... they often suffer irreversible brain damage. A Mayo Clinic study ... guidance to physicians using therapeutic cooling to treat sudden cardiac ...
... Finding innovative, minimally invasive ways to treat liver cancerand ... hallmarks of interventional radiologists. Advances in yttrium-90 (Y-90) radioembolization ... worldwide, are reported in studies in the October ... of these two new studies may be beneficial to ...
... Women still have hot flushes and night sweats years after the ... International Journal of Obstetrics and Gynaecology . Hot flushes and ... however their prevalence, frequency, severity and duration vary considerably. ... is 50-51 years and it is generally assumed that HF/NS last ...
... , William Tierney, MD, is to receive the 2011 ... informatics professionals, in recognition of his personal commitment and ... impression on the field. Dr. Tierney, president and CEO ... Indiana University School of Medicine and holds the Sam ...
Cached Medicine News:Health News:More Facebook Friends, More Gray Matter in Brain? 2Health News:More Facebook Friends, More Gray Matter in Brain? 3Health News:Hypertension, Not Blood Pressure Drugs, Linked to Birth Defects 2Health News:Mayo Clinic study guides physicians using therapeutic cooling to treat cardiac arrest patients 2Health News:Interventional radiologists: Tough on liver cancer, kind to patients 2Health News:Interventional radiologists: Tough on liver cancer, kind to patients 3Health News:Interventional radiologists: Tough on liver cancer, kind to patients 4Health News:Older women still suffer from hot flushes and night sweats years after the menopause finds study 2Health News:AMIA honors Regenstrief Institute's President and CEO with 2011 Morris F. Collen Award 2Health News:AMIA honors Regenstrief Institute's President and CEO with 2011 Morris F. Collen Award 3
... Centra B+ can be used as a manual ... Centra W for AHG spins, or as a ... rotors, transparent cell washing rotor: easy to see ... options, aerosol containment for vacutainers, glove friendly membrane ...
... programmable refrigerated floor-standing centrifuge. Mobile space ... large choice of accessories, microprocessor control, ... 4 languages, imbalance detection & shutdown ... dual lid interlock, current and temperature ...
... Powerful programmable refrigerated bench-top ... capacity rotors, large choice ... sample protection, true sample ... lifetime reproducibility, true RCF, ...
GP8R is a powerful 3-liter large capacity centrifuge which is flexible and easy to use with refrigeration facility. Performs separations 50-100% faster than the rest, powerful, accommodating and conv...
Medicine Products: